Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Titel:
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
Auteur:
Alés-Martínez, José Enrique Balmaña, Judith Sánchez-Rovira, Pedro Salvador Bofill, Francisco Javier García Sáenz, Jose Ángel Pimentel, Isabel Morales, Serafín Fernández-Abad, María Lahuerta Martínez, Ainhara Ferrer, Neus Zamora, Pilar Bermejo, Begoña Díaz-Redondo, Tamara López-Ceballos, María Helena Galán, María Pérez-Escuredo, Jhudit Calabuig, Laura Sampayo, Miguel Pérez-Garcia, José Manuel Cortés, Javier Llombart-Cussac, Antonio